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Summary 
We have analyzed the relative contribution of dendritic cells (DC) and B cells in the presenta- 
tion of peptide--class  II complexes in an inflammatory situation in vivo. Draining lymph node 
cells from mice immunized subcutaneously with hen egg-white lysozyme (HEL) in adjuvant 
display HEL peptide-major histocompatibility complex class II complexes able to stimulate, in 
the absence of any further antigen addition, specific T  hybridoma cells. The antigen-presenting 
capacity of three different antigen-presenting cell (APC) populations recruited in lymph nodes, 
DC  (N418 +, class II  +, B220-, low buoyant density), large B  cells (B220  +, low buoyant den- 
sity), and small B cells (B220 +, high buoyant density), was analyzed. After immunization with 
HEL in adjuvant, DC are the only lymph node APC population expressing detectable HEL 
peptide-class II complexes. These results  indicate that lymph node DC and not B cells are the 
APC initiating the immune response in vivo after administration of antigen in adjuvant. 
F 
leptides bound to class II MHC molecules on the sur- 
face of APC are the ligands for antigen-specific recep- 
tors of CD4 § T  cells  (1).  Among the different APC pop- 
ulations, dendritic cells  (DC), 1 as compared to other class 
II-bearing  cells  such  as  macrophages  (M+)  and  B  cells, 
have been shown  to be  crucial for activation of naive T 
cells specific for protein antigens both in vitro (2-4) and in 
vivo  (5).  A  remarkable characteristic of DC  is  their high 
expression, in  addition to MHC  molecules,  of adhesion/ 
costimulatory molecules  (2,  6,  7).  This may explain their 
efficiency in presenting exogenous (2,  3,  8)  and  endoge- 
nous (9) antigen to class II-restricted T  cells. 
DC appear to be critical for the initiation of the CD4 + T 
cell responses in vivo, whereas B cells can activate antigen- 
experienced but not naive CD4 § T  cells (10,  11). This hy- 
pothesis is strongly supported by a recent study in B  cell- 
deficient mice emphasizing the importance of DC,  rather 
than B  cells,  in the priming of antigen-specific CD4 +  or 
CD8 § T  cells  (12).  However, based on studies in anti-pT 
treated mice, it has been shown that B cells are required for 
the  in vivo priming of T  cell proliferative responses  (13, 
14). The defective T  cell priming induced by anti-p~ treat- 
ment could be overcome by injection of purified normal 
(15) or antigen-specific (16) B  cells. Thus, it has been hy- 
pothesized that B  cells could control the clonal expansion 
1Abbreviations  used in  this paper: DC,  dendritic  cell; Mqb, macrophage; 
LNC,  lymph node cells; m[32M, mouse  [32 microglobulin;  HEL,  hen 
egg-white lysozyme. 
of T  cells  and/or drive the diversification of the immune 
response (17). 
In  most  of the  studies  mentioned  above,  the  relative 
contribution of B  cells  as  compared to professional APC 
such as DC, in antigen presentation in vivo, has been ana- 
lyzed indirectly,  using  as  read  out  the  priming  of T  cell 
proliferative responses. CD4 § T  cell activation depends on 
different factors, but the essential  one is the presentation of 
peptide-class II complexes by APC. After intravenous ad- 
ministration of protein, it has been shown that splenic DC 
are the main cells bearing immunogenic fragments of for- 
eign  antigens  (18).  However,  the  phenotype  of lymph 
node APC expressing antigenic complexes after subcutane- 
ous administration of antigen in adjuvant is not known. To 
clarify this issue,  we have analyzed the relative capacity of 
lymph node  DC  and B  cells  to present peptides  derived 
from in vivo processing of protein antigen administered in 
adjuvant. This experimental model is based on our previ- 
ous observation that draining lymph node cells (LNC) from 
mice immunized with hen egg-white lysozyme (HEL) dis- 
play HEL peptide-MHC class II complexes able to stimu- 
late, in the absence of any further antigen addition, specific 
T  hybridoma cells (19, 20). 
In the present paper, we characterize the phenotype of 
the lymph node APC bearing antigenic complexes by ana- 
lyzing both the expression of cell surface markers and their 
intrinsic  capacity to present an endogenously synthesized, 
naturally processed self-epitope, the mouse [32-microglob- 
ulin  ([32M)  peptide 26-39 bound to I-A  d molecules (21). 
Three APC populations were purified from immune lymph 
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by irnmunobeads;  their ability to activate class II-restricted 
T  cell hybridomas was determined.  In agreement with our 
previous study (9),  the hierarchy in the capacity to present 
the  naturally  processed  self-epitopes  of [32M  by  lymph 
node APC is DC >  large B cells  >  small B ceils.  After sub- 
cutaneous administration of HEL in adjuvant, the presenta- 
tion  of HEL peptides  complexed  to  class  II molecules  is 
exclusively restricted to a low buoyant density APC popu- 
lation expressing DC markers N418 (CD 1 lc) +, MHC class 
II  high, F4/80-, and B220-. 
Materials  and Methods 
Mice, Antigens, and Immunization.  2-3-mo-old  BALB/c  and 
C3H mice (Charles  River Italy, Calco, Italy) of either sex were 
used. HEL, recrystallized three times and bovine RNase were ob- 
tained from Sigma  Chemical Co.  (St. Louis,  MO).  Mice were 
immunized subcutaneously into the hind footpads with the indi- 
cated amount of antigen  emulsified  in IFA or CFA containing 
H37Ra mycobacteria (Difco Laboratories,  Detroit, MI). 
Assay for Antigen-presenting Activity of LNC from HEL-ptimed 
Mice.  The  antigen-presenting  activity  of LNC  from  HEL- 
primed mice was assessed as previously described (19) using the 
following T cell hybridomas: 1C5.1 (I-A  k, HEL46-61) (19), 3Bl1.1 
(I-A  k,  HEL34-45)  (22),  1Hll.3  (I-E  d,  HELl08-116)  (23),  and 
2G12.1  (I-A  d,  [32M26-39)  (21).  Briefly,  mice were immunized 
into  the  hind  footpads  with  the  indicated  amount  of antigen 
emulsified in IFA or CFA. 5-6 d after immunization, the draining 
popliteal  lymph nodes were removed, and APC prepared as de- 
scribed below. Lymph node APC were then cultured in duplicate 
or triplicate at the indicated cell doses with appropriate HEL-spe- 
cific T  cell  hybridomas (5  ￿  104 cells/well)  in 96-well culture 
plates  (Costar  Corp.,  Cambridge,  MA).  Culture  medium  was 
RPMI  1640  (Gibco,  Basel, Switzerland)  supplemented  with  2 
mM L-glutamine,  50  b~M 2-ME,  50  b~g/ml gentamicin  (Sigma 
Chemical  Co.),  and  10%  FCS  (Gibco).  After 24  h  of culture, 
50-~1  aliquots  of supematants  were transferred  to microculture 
wells containing 104 CTLL cells and, after an additional  24-h in- 
cubation, the presence of T cell growth factors, mainly IL-2, was 
assessed by [3H]TdR incorporation during the last 5 h of culture. 
Cytokine Assays.  IL-2 concentration was also determined us- 
ing a two-site sandwich  ELISA with paired  mAb purchased from 
PharMingen (San Diego, CA). For capture, the mAb was JES6- 
1A12 (rat anti-mouse IL-2). Samples were titrated  in test solution 
(PBS  containing 5%  FCS  and  1  g/liter  phenol)  and incubated 
overnight at  4~  To detect bound cytokines, plates  were then 
incubated with the biotinylated rnAb JES6-5H4 (rat anti-mouse 
IL-2)  in  PBS  containing 0.1%  Tween  20  and  1%  BSA.  After 
washing,  the bound biotinylated antibodies  were revealed  by an 
additional  30-rain  incubation  with  alkaline  phosphatase-conju- 
gated streptavidin  (Jackson  ImmunoResearch Laboratories,  Inc., 
West  Grove,  PA)  diluted  1/10,000.  The  plates  were  washed 
again  and  incubated  with  the  developing substrate  p-nitrophe- 
nylphosphate disodium (Sigma Chemical Co.) in diethanolamine 
buffer, pH 9.6 (100 ~l/well). The reaction was stopped by adding 
50 I.L1/well NaOH 3N and absorbance  was read at 405 nm. IL-2 
was quantified  from two to three titration points using standard 
curves  generated  by purified  recombinant  mouse  IL-2;  results 
were expressed  as cytokine concentration in pg/ml.  The detec- 
tion limit was 10 pg/ml. 
APC Preparation.  Immune LNC were depleted  of T  cells by 
cytotoxic elimination with HO-13-4 anti-Thy 1.2 mAb (TIB 99) 
followed by rabbit complement (low-tox M|  Cedarlane Labora- 
tories,  Ltd., Hornby, ON, Canada).  Low and high buoyant den- 
sity APC were prepared from T  cell-depleted LNC by centrifu- 
gation  over  a  discontinous  Percoll  gradient  (Pharmacia  LKB, 
Uppsala, Sweden)  containing 55-60% and 70% layers. Cells at the 
medium/55-60% and 60/70 % interface were collected separately 
and referred to as low and high buoyant density APC,  respec- 
tively.  Cells  from  the  low  density  population  were  incubated 
with B220-coated microbeads and then separated into B220 + and 
B220-  fractions  on MiniMACS  |  separation  columns  (Miltenyi 
Biotec GmbH, Bergisch Gladbach,  Germany). Similarly, N418 + 
cells were sorted by incubating T cell-depleted LNC with bioti- 
nylated N418 mAb and streptavidin-coated  microbeads before en- 
richment by passage on a MiniMACS  |  separation  column. N418 
is a hamster mAb specific for mouse splenic DC recognizing the 
p150/90 leukocyte integrin,  likely  the mouse CDllc  molecule 
(24, 25). 
Flow Cytometry.  Cells  were  double  stained  by  incubating 
them with optimal concentrations of FITC-labeled mAb and bi- 
otin-conjugated N418 mAb (anti-CD11c) for 30 rain at 4~  in 
PBS containing 5% FCS, 0.1% sodium azide,  and 1% normal rat 
serum to inhibit binding to FcR. The following FITC-conjugated 
mAb were used: SF1-1.1  (anti-Ka),  14.4.4S (anti-l-E), 6B2 (anti- 
B220),  and Mac-1  (anti-CD11b),  all purchased from PharMin- 
gen, and F4/80  (Serotec  Ltd.,  Oxford, UK).  Biotinylated mAb 
were  revealed  using  PE-streptavidin  (Southern  Biotechnology 
Associates Inc., Birmingham, AL). Analysis was performed on a 
FACScan  |  flow cytometer (Becton Dickinson & Co., Mountain 
View, CA). Data were collected on 5,000-10,000 viable  cells as 
determined by foward light scatter  intensity and propidium io- 
dide exclusion,  and were analyzed using Lysis II software  (Becton 
Dickinson & Co.). 
Results 
The Antigen-presenting Activity in Immune LNC Is Restrict- 
ed to the Low Buoyant Density Population.  We  have  previ- 
ously shown that APC in draining lymph nodes from mice 
immunized  subcutaneously  with  HEL  in  adjuvant  display 
antigenic  complexes formed in vivo between peptides  de- 
rived from HEL processing and class II molecules (19, 20). 
After immunization  with  HEL in  IFA or CFA,  antigenic 
complexes are readily detectable on lymph node APC from 
day  2  to  14  after immunization  (not shown).  To  analyze 
the phenotype of lymph node APC bearing HEL peptide- 
class II complexes, we first separated T  ceil-depleted LNC 
in  low  and  high  buoyant  density populations.  Results  in 
Fig. 1 show that all the antigen-presenting activity is recov- 
ered in the low density fraction,  enriched in large B  ceils 
and DC/Md~.  Lymph node APC from HEL-primed C3H 
mice  were  monitored  for  their  capacity  to  present  com- 
plexes  formed  between  two  dominant  HEL  epitopes, 
HEL34-45 and HEL46-61  bound to I-A  k molecules  (Fig. 
1, A  and B). For both determinants,  a 30-100-fold enrich- 
ment in antigen-presenting activity is displayed by the low 
density  population,  as  compared  to  unseparated  T  ceil- 
depleted LNC.  Similar results  are obtained by monitoring 
the  formation  of HEL108-116/E  d complexes  in  BALB/c 
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Figure  1.  Presentation of exogenous HEL peptide-class I1 complexes 
and naturally processed self 132M epitopes by low buoyant density lymph 
node APC. C3H (A and B) or BALB/c (C and D) mice were immunized 
into the hind footpads with  10 nmol HEL in IFA. 7 d later, draining 
popliteal LNC from five mice/group were pooled and T cells depleted by 
cytotoxic elimination with anti-Thy-1 mAb + C'. Cells were then sepa- 
rated in low and high buoyant density by centrifugation on 55% Percoll 
solution. The indicated numbers of T cell-depleted (C)), low buoyant 
density T cell-depleted (O), or high density T cell-depleted (ff]) LNC 
were then cultured with the indicated T cell hybridomas. APC were not 
irradiated before ctflture. After 24 h, antigen-specific IL-2 production was 
determined by adding 50-~1 aliquots of culture supernatant to 104 CTLL 
cells for an additional 24 h. [3H]Thymidine (1 I~Ci/well) was added dur- 
ing the last 5 h of culture. Data are presented as mean thymidine incorpo- 
ration (cpm) from duphcate cultures. Background proliferation of CTLL 
was usually <1,000  cpm. The following number of cells was recovered 
after each step: T cell--depleted (80 ￿  106; 35 ￿  106); high density (36 ￿ 
106; 9.5 ￿  106) and low density (1.2 ￿  106; 0.98 ￿  106) from BALB/c 
and C3H mice, respectively. Results are from one representative experi- 
ment out of  five performed with similar results. 
mice (Fig.  1 C).  In this mouse strain we have developed a 
system to analyze presentation  by I-A  a molecules  of natu- 
rally processed self-[32M peptides  corresponding to the se- 
quence  26-39  (21).  Results  in  Fig.  1 D  show that,  as  for 
presentation  of complexes  derived from processing of ex- 
ogenous HEL, a similar hierarchy of 132M presentation by 
different  APC  is  observed  using as  read  out  the  [32M26- 
39-specific, I-Aa-restricted T  cell hybridoma 2G12.1  (21). 
Similar  results  were  obtained using as  read  out [32M-spe- 
cific, I-Ea--restricted T  hybridoma cells (not shown). 
Antigenic Complexes Are Detectable only on DC-like APC in 
Immune Lymph Node.  In  steady  state  mouse  spleen,  DC 
are the most efficient in presenting endogenous naturally pro- 
cessed 132M epitopes  (9),  suggesting that most of the HEL- 
presenting activity in immune lymph node APC could also 
be restricted to this cell population. Therefore, by a combi- 
nation of Percoll gradient centrifugation and magnetic cell 
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sorting, we separated lymph node APC into three popula- 
tions (Fig. 2). These populations were characterized by their 
expression  of MHC  class  II, B220,  and  N418  molecules. 
The N418 hamster mAb recognizes CDllc, an integrin ex- 
pressed  on DC  and  at  low level  on Md~  in  normal  lym- 
phoid  tissues  (24).  As  shown  in  Fig.  2,  the  high  density 
population  from  T  cell-depleted  LNC  contains  mainly 
B220 +  I-E  + cells.  Conversely, the low density population 
(90%  class  II  +)  is composed by a mixture  of N418 +  I-E  + 
(30%)  and B220 + I-E  +  (58%)  cells.  Results in Fig. 3  show 
the  double  staining  analysis  of low  density  lymph  node 
APC.  N418 +  gated cells  are  negative  for the  Mqb  marker 
F4/80, whereas 49% are positive for Mac-1. They display a 
heterogeneous expression of MHC  class II molecules (25% 
low, 75% high) and are negative for B220 molecules. There- 
fore,  the  low  density population  was labeled  with  B220- 
coated  microbeads  and  then  sorted  in  B220 +  and  B220- 
cells.  The  population  positively  selected  by B220-coated 
microbeads contains mostly class II  + B cells (97%), whereas 
the negatively sorted one is enriched (60-70%) in DC-like 
cells  expressing  high  levels  of CDllc  and  MHC  class  II 
molecules.  Similar results were  obtained using LNC from 
mice primed with HEL either in IFA or CFA, or with IFA 
only (not shown).  These  different APC populations  were 
then tested for their capacity to activate T  cell hybridomas 
specific for self 132M26-39/A  d and exogenous HELl08-116/ 
E a complexes. As shown in Fig. 4, the hierarchy of endog- 
enously synthesized self-[32M presentation is similar to that 
previously observed with splenic APC (9): DC-hke >  large 
B  cells  >  small  B  cells  for both  APC  from IFA or CFA 
primed  mice.  It is  interesting  to note  that  complexes  de- 
rived from exogenous HEL are only detectable on the DC- 
like  population,  whereas  B  cells,  although able  to present 
endogenous  peptide,  fail  to  present  exogenous  antigen. 
APC from IFA- or CFA-primed mice have a  comparable 
capacity to present the self-132M peptide,  but presentation 
of HEL-derived peptide  is much more efficient using DC 
from HEL-IFA- as compared to HEL-CFA-primed mice. 
Direct Correlation between Enrichment of N418 §  Cells and 
Increase inAntigenPresentation.  Cell  sorting  by  the  N418 
mAb has been successfully used to enrich DC from mouse 
spleen  (25).  To confirm the role of DC in our model, we 
tested whether isolation of the N418 §  cell subset by posi- 
tive selection using magnetic cell sorting would result in an 
enrichment  of HEL-presenting  activity  (Fig.  5).  T  cell- 
depleted  LNC from mice primed with HEL in IFA were 
labeled with biotinylated N418 mAb followed by streptavi- 
din-conjugated  microbeads  before  separation  on  a  Mini- 
MACS  |  column. The yield of sorted N418 + cells (70% en- 
riched) at the end of the procedure is ~1% of the total cells 
recovered in the negatively selected population (see legend 
to Fig. 5).  N418-sorted cells expressed Mac-1  but not the 
F4/80  antigen,  as in Fig.  3,  indicating  that Mqb were not 
selected.  Morphologically,  after overnight culture,  N418 + 
cells were highly enriched in nonadherent  cells  exhibiting 
the  large  veils  characteristic  of DC  (not  shown).  When 
HEL peptide-class  II complexes  expressed  by these  APC 
populations  are  monitored,  N418-sorted  cells  display,  as Thy 1.2-  Cells 
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Figure  2.  Separation  of  lymph  node 
APC. BALB/c mice were immunized with 
10 nmol HEL in IFA. 5 d later, LNC from 
five mice were pooled,  depleted  of T  cells, 
and separated in low and high density popu- 
lation  by  centrifugation  on  Percoll.  Cells 
were  double  stained  for  N418/I-E  and 
B220/I-E  expression.  Low  density  APC 
were  further  separated  by  magnetic  cell 
sorting  on  a  MiniMACS  |  column  using 
B220-conjugated  microbeads.  Both  posi- 
tively  and  negatively  selected  populations 
are  analyzed  for cell  surface expression  of 
the indicated  molecules.  The yield  of cells 
recovered after each  separation  step (mean 
percentage  of total  LNC  4-  SD from nine 
experiments)  was:  T  cell-depleted  (42  • 
3.7); high density (17.7 4- 9.6); low density 
(2.43  4-  1.35); low density B220 + (0.96 -+ 
0.56) and low density B220  (0.56 4- 0.25). 
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Figure 3.  Cytofluorimetric analysis of lymph node DC. Low density, 
T cell-depleted LNC were obtained  as in Fig. 2 t]'om LNC of BALB/c 
mice primed with  10 nmol HEL in IFA 6 d earlier. Cells were double 
stained by FITC-conjugated mAb specific for the indicated molecules and 
by N418-biotin followed by streptavidin-PE.  Cell surface expression of 
the indicated  molecules  (closed histograms) was  analyzed on the N418 +- 
gated population￿9 Control staining (open histograms) represents cells stained 
without FITC-mAb. 
compared  to  T  cell-depleted LNC,  a  100-fold  increase  in 
the HEL peptide-presenting  activity which  correlates with 
the  enrichment  of this  cell population  with  ~0.7  to  70% 
(Fig.  5).  Again,  the  antigen-presenting  activity was  higher 
for  N418 +  cells  from  IFA-  as  compared  to  CFA-primed 
mice.  A  two-  to  threefold  decrease  in  antigen-presenting 
activity is observed in the negatively selected cells. The re- 
maining antigen-presenting  activity could  be explained by 
residual N418 §  ceils that were not positively selected. 
Collectively,  these  results  indicate  that  after  subcutane- 
ous  administration  of protein  in  adjuvant,  antigenic  com- 
plexes  are  only  detectable  on  a  DC-like  population  ex- 
pressing  the  N418  marker,  whereas  B  cells  are  devoid  of 
antigen-presenting activity. 
Discussion 
We have studied the relative capacity of lymph node DC 
and  B  cells to  present  in vivo to  class  II-restricted  T  cells 
peptides derived from the processing of protein antigen ad- 
ministered  in  adjuvant.  By  monitoring  HEL108-116/E d 
complexes after subcutaneous  administration  of HEL in ad- 
juvant,  peptide-class  II complexes are exclusively detected 
on the low density N418 + APC subset.  Unlike B  cells, im- 
mature DC, such as Langerhans cells in the skin, are present 
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Figure 4.  Antigenic complexes are expressed only by lymph node DC 
after administration of protein antigen in adjuvant. BALB/c mice were 
immunized with  10 nmol HEL in IFA (A and C) or CFA (B and D). 
LNC from five mice per group were pooled and APC populations sepa- 
rated as in Fig. 2. The self ~2M-specific, I-Aa-restricted 2G12.1, and the 
HEL-specific I-Ea-restricted 1Hll.3 T cell hybridomas (top and bottom, 
respectively) were cultured (5 ￿  104 cells/well) with graded numbers of 
enriched APC populations. After 24 h of culture, IL-2 production was 
determined as in Fig. 1. Results are from one representative experiment 
out of five performed with similar results. 
at the injection site where they exert a sentinel function (2, 
26). It is therefore likely that protein has been endocytosed 
by resident immature DC, then processed and presented ef- 
ficiently by DC recruited in the lymph node, where prim- 
ing of naive T  cells may occur. Several lines of evidence in- 
dicate that lymph node N418 + cells belong to the dendritic 
cell system. First, in addition to the CD11c  (N418) marker, 
they express high levels of MHC  class II molecules and are 
positive  for  CDllb  (Mac-l)  but  negative  for  the  Mqb 
marker  F4/80.  Second,  after  sorting  by  N418  mAb  and 
overnight  culture,  this  population  is  highly  enriched  in 
nonadherent cells exhibiting the large veils characteristic of 
DC.  Third,  they are  the  most  efficient in  presenting en- 
dogenous self-j32M peptide-class II complexes, as we have 
recently shown for thymic and splenic DC (9). 
It is interesting to  note  that  all three  APC  populations 
tested,  DC,  large  and  small B  ceils,  are  recruited  to  the 
draining lymph node independently of the presence of My- 
cobacterium  or antigen  in  the  adjuvant.  This  is in  agree- 
ment with the hypothesis that tissue injury, induced in our 
system by subcutaneous administration of adjuvant, is suffi- 
cient  to  induce  the  migration  of APC,  including DC,  to 
lymphoid organs (27).  Immunization by antigen emulsified 
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Figure 5.  Direct correlation between N418 + cell enrichment and anti- 
gen presentation. BALB/c mice were immunized with 10 nmol HEL in 
IFA (A and C) or CFA (B and D). 5 d later, LNC from five mice per 
group were pooled and depleted of T cells. APC populations were en- 
riched in N41B  + cells  by magnetic cell sorting on a MiniMACS  |  columns 
using hiotin-conjugated N418 mAb and streptavidin microbeads. The in- 
dicated numbers of T cell-depleted unsorted APC  (O), N418-enriched 
(E]), or negatively selected N418 cells (A) were cultured with the self- 
132M-specific T cell hybridoma 2G12.1 (A and B), or with the HELl08- 
116 specific, l-Ea-restricted T  cell hybridoma 1Hll.3 (C and D). The 
N418-sorted cells represent 0.8% (IFA) and 0.7% (CFA) of the negatively 
selected, T cell-depleted LNC. After 24 h of culture, IL-2 concentration 
was determined by two-site sandwich ELISA. Results are from one ex- 
periment out of two performed with similar results. 
in CFA or IFA leads to the recruitment of similar numbers 
ofN418 § cells in draining lymph nodes. However, the anti- 
gen-presenting activity is higher in APC from mice primed 
with  protein  antigen  emulsified in  IFA rather  than  CFA. 
Several explanations could account  for this  difference.  As 
we have previously shown for MHC  class II-blocking pep- 
tides (19),  peptides from Mycobacterium  tuberculosis proteins 
present in CFA could compete with HEL-derived peptides 
for antigen presentation. Alternatively, components in CFA 
might increase the local secretion of proinflammatory cyto- 
kines such as TNF-ot, which has been shown to downreg- 
ulate the antigen-capturing and -processing capacity of hu- 
man DC in vitro (28). However, changes in the stimulatory 
function of DC do not appear to play a role in our system 
because no differences were observed in their intrinsic ca- 
pacity to activate T  cell hybridomas specific for the self J32M 
peptide.  Therefore,  competition  for  antigen  presentation 
and/or induction of DC maturation, rather than changes in 
their immunostimulatory capacity, could explain these dif- 
ferences.  T  cell priming is usually more  efficient in mice 
immunized with  antigen in CFA than in  IFA, and  there- 
755  Gu6ry et al. fore it  does  not  correlate  with  the  antigen-presenting  ca- 
pacity of lymph node DC.  It is possible that priming  of a 
high frequency ofMycobacterium-specific T  cells could pro- 
vide substantial help to the development of HEL-specific T 
cells because of increased local production oflL-2. In addi- 
tion, immunization in CFA might favor IL-12 production, 
which would result in a stronger polarization  of the T  cell 
response  towards  the  Thl  phenotype,  characterized  by 
IFN-~/  and  IL-2  production  associated  with  increased  T 
cell proliferation  (29).  All  these  mechanisms  may contrib- 
ute to compensate for the decreased capacity of DC to pre- 
sent peptides derived from exogenous proteins administered 
in CFA. 
The  demonstration  that  DC  are  the  only APC  able  to 
display  antigen-presenting  capacity  after subcutaneous  ad- 
ministration  of antigen  in  adjuvant  strongly  supports  the 
hypothesis  that  DC  rather  than  B  cells  are  required  for 
priming ofT  cell proliferative responses in vivo (5,  10,  11, 
30,  31).  Direct  evidence  for this  hypothesis  has been  re- 
cently provided by the  demonstration  of successful T  cell 
priming in B  cell-deficient mice (12). Using anti-p~-treated 
mice, B  cells have also been implicated in the priming of T 
cell  responses  in  vivo  (13-16).  Administration  of rabbit 
anti-p~  Ig from birth  results  in B  cell  depletion  associated 
with defective T  cell proliferation that could be restored by 
B  cell transfer (15,  16). Chronic stimulation of the immune 
system could favor the  development  of antigen-specific  T 
cells with Th2 phenotype  (32), which proliferate less than 
Thl  cells (33). The fact that B  cell transfer overcomes inhi- 
bition of T  cell proliferation in a MHC  nonrestricted fash- 
ion  (15)  could  be  explained  by the  capacity  of B  cells  to 
consume endogenous  IL-4, which in turn would favor the 
development of a proliferative Thl  response. 
In conclusion,  lymph node  DC,  unlike  B  cells,  present 
very  efficiently  antigenic  peptides  derived  from  the  pro- 
cessing of protein antigen endocytosed at the site of inflam- 
mation.  These results indicate  that DC and not B  cells are 
the initiating APC in immune lymph nodes.  IL-12 admin- 
istration to nonobese diabetic mice results in acceleration of 
autoimmune  diabetes,  associated  with  massive  infiltration 
of lymphoid cells, including N418 + cells, into the pancreas 
(34). Considering the efficiency of DC in antigen presenta- 
tion  and  their  capacity to produce  IL-12  (35,  and  Gurry, 
J.-C., F. ILia, and L. Adorini,  manuscript in preparation), it 
is  possible  that  pancreatic  N418 +  cells  play  a  role  in  the 
induction  of autoreactive T  cells.  If this is the case, target- 
ing DC may be an interesting approach to prevent autoim- 
munity. 
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